A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Summary

This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.

Timeline

Start

2022-12-12

Primary completion

2028-02

Completion

2028-02

Drugs

Indications